116 related articles for article (PubMed ID: 33814238)
21. High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection.
Rödel F; Hoffmann J; Grabenbauer GG; Papadopoulos T; Weiss C; Günther K; Schick C; Sauer R; Rödel C
Strahlenther Onkol; 2002 Aug; 178(8):426-35. PubMed ID: 12240548
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant therapy for rectal cancer: histologic response of the primary tumor predicts nodal status.
Read TE; Andujar JE; Caushaj PF; Johnston DR; Dietz DW; Myerson RJ; Fleshman JW; Birnbaum EH; Mutch MG; Kodner IJ
Dis Colon Rectum; 2004 Jun; 47(6):825-31. PubMed ID: 15108025
[TBL] [Abstract][Full Text] [Related]
23. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis.
Renehan AG; Malcomson L; Emsley R; Gollins S; Maw A; Myint AS; Rooney PS; Susnerwala S; Blower A; Saunders MP; Wilson MS; Scott N; O'Dwyer ST
Lancet Oncol; 2016 Feb; 17(2):174-183. PubMed ID: 26705854
[TBL] [Abstract][Full Text] [Related]
24. Treatment and survival of locally recurrent rectal cancer: A cross-sectional population study 15 years after the Dutch TME trial.
Detering R; Karthaus EG; Borstlap WAA; Marijnen CAM; van de Velde CJH; Bemelman WA; Beets GL; Tanis PJ; Aalbers AGJ;
Eur J Surg Oncol; 2019 Nov; 45(11):2059-2069. PubMed ID: 31230980
[TBL] [Abstract][Full Text] [Related]
25. Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: do we have indications for individual risk stratification?
Sprenger T; Rothe H; Jung K; Christiansen H; Conradi LC; Ghadimi BM; Becker H; Liersch T
World J Surg Oncol; 2010 Apr; 8():27. PubMed ID: 20388220
[TBL] [Abstract][Full Text] [Related]
26. Pretreatment expression of 13 molecular markers as a predictor of tumor responses after neoadjuvant chemoradiation in rectal cancer.
Huh JW; Lee JH; Kim HR
Ann Surg; 2014 Mar; 259(3):508-15. PubMed ID: 23787217
[TBL] [Abstract][Full Text] [Related]
27. [Efficacy analysis of neoadjuvant chemoradiotherapy combined with total pelvic exenteration in the treatment of primary T4b rectal cancer].
Wu T; Wen L; Zhang J; Wu Y; Jiang Y; Chen G; Wang X; Huang S; Wan Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):59-65. PubMed ID: 30703795
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant Chemotherapy Does Not Improve Recurrence-Free Survival in Patients With Stage 2 or Stage 3 Rectal Cancer After Neoadjuvant Chemoradiotherapy and Total Mesorectal Excision.
Voss RK; Lin JC; Roper MT; Al-Temimi MH; Ruan JH; Tseng WH; Tam M; Sherman MJ; Klaristenfeld DD; Tomassi MJ
Dis Colon Rectum; 2020 Apr; 63(4):427-440. PubMed ID: 31996583
[TBL] [Abstract][Full Text] [Related]
29. Comparison of Different Nodal Staging in Patients With Locally Advanced Mid-low Rectal Cancer After Long-term Neoadjuvant Chemoradiation Therapy.
Petrucciani N; Carra MC; Martínez-Pérez A; Vitali GC; Landi F; Genova P; Memeo R; Brunetti F; Espin E; Ris F; De'angelis N;
Anticancer Res; 2019 Apr; 39(4):2113-2120. PubMed ID: 30952757
[TBL] [Abstract][Full Text] [Related]
30. The significance of mucin pools following neoadjuvant chemoradiotherapy for locally advanced rectal cancer.
Reynolds IS; McNamara DA; Kay EW; O'Neill B; Deasy J; Burke JP
J Surg Oncol; 2018 Dec; 118(7):1129-1134. PubMed ID: 30261095
[TBL] [Abstract][Full Text] [Related]
31. Refining the Use of Adjuvant Oxaliplatin in Clinical Stage II or III Rectal Adenocarcinoma.
Margalit O; Mamtani R; Kopetz S; Yang YX; Lawrence YR; Abu-Gazala S; Reiss KA; Golan T; Halpern N; Aderka D; Giantonio B; Shacham-Shmueli E; Boursi B
Oncologist; 2019 Aug; 24(8):e671-e676. PubMed ID: 30696723
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Value of Clinical vs Pathologic Stage in Rectal Cancer Patients Receiving Neoadjuvant Therapy.
Delitto D; George TJ; Loftus TJ; Qiu P; Chang GJ; Allegra CJ; Hall WA; Hughes SJ; Tan SA; Shaw CM; Iqbal A
J Natl Cancer Inst; 2018 May; 110(5):460-466. PubMed ID: 29165692
[TBL] [Abstract][Full Text] [Related]
33. The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma.
Edden Y; Wexner SD; Berho M
Colorectal Dis; 2012 May; 14(5):555-61. PubMed ID: 21689364
[TBL] [Abstract][Full Text] [Related]
34. What Is the Utility of Restaging Imaging for Patients With Clinical Stage II/III Rectal Cancer After Completion of Neoadjuvant Chemoradiation and Prior to Proctectomy?
Hendrick LE; Buckner JD; Guerrero WM; Shibata D; Hinkle NM; Monroe JJ; Glazer ES; Deneve JL; Dickson PV
Am Surg; 2021 Feb; 87(2):242-247. PubMed ID: 32927959
[TBL] [Abstract][Full Text] [Related]
35. Cytoplasmic CD133 expression is a reliable prognostic indicator of tumor regression after neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer.
Jao SW; Chen SF; Lin YS; Chang YC; Lee TY; Wu CC; Jin JS; Nieh S
Ann Surg Oncol; 2012 Oct; 19(11):3432-40. PubMed ID: 22739652
[TBL] [Abstract][Full Text] [Related]
36. Securin identifies a subgroup of patients with poor outcome in rectal cancer treated with long-course (chemo)radiotherapy.
Avoranta ST; Korkeila EA; Minn HR; Syrjänen KJ; Pyrhönen SO; Sundström JT
Acta Oncol; 2011 Nov; 50(8):1158-66. PubMed ID: 22023115
[TBL] [Abstract][Full Text] [Related]
37. Does A Longer Waiting Period After Neoadjuvant Radio-chemotherapy Improve the Oncological Prognosis of Rectal Cancer?: Three Years' Follow-up Results of the Greccar-6 Randomized Multicenter Trial.
Lefèvre JH; Mineur L; Cachanado M; Denost Q; Rouanet P; de Chaisemartin C; Meunier B; Mehrdad J; Cotte E; Desrame J; Karoui M; Benoist S; Kirzin S; Berger A; Panis Y; Piessen G; Saudemont A; Prudhomme M; Peschaud F; Dubois A; Loriau J; Tuech JJ; Meurette G; Lupinacci R; Goasguen N; Creavin B; Simon T; Parc Y;
Ann Surg; 2019 Nov; 270(5):747-754. PubMed ID: 31634178
[TBL] [Abstract][Full Text] [Related]
38. [Predictive factors of pathological complete response after neoadjuvant chemoradiotherapy for middle-low rectal cancer].
Liu QZ; Zhang H; Hao LQ; Lou Z; Liu LJ; Gao XH; Gong HF; Hong YG; Xin C; Zhang W
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Dec; 23(12):1159-1163. PubMed ID: 33353270
[No Abstract] [Full Text] [Related]
39. Does IBD Portend Worse Outcomes in Patients with Rectal Cancer? A Case-Matched Analysis.
Alsughayer A; Grass F; McKenna NP; Petersen M; Mathis KL; Lightner AL
Dis Colon Rectum; 2020 Sep; 63(9):1265-1275. PubMed ID: 33216497
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of neoadjuvant intensity-modulated radiotherapy with concurrent capecitabine for locally advanced rectal cancer.
Wang L; Li ZY; Li ZW; Li YH; Sun YS; Ji JF; Gu J; Cai Y
Dis Colon Rectum; 2015 Feb; 58(2):186-92. PubMed ID: 25585076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
